Multipl Myeloma Böbreği
Yıl: 2015 Cilt: 24 Sayı: 3 Sayfa Aralığı: 256 - 265 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Multipl Myeloma Böbreği
Öz: Semptomatik multipl myelomalı (MM) hastalarda böbrek hasarı sık görülen ve hasta sağkalımını etkileyen bir komplikasyondur. MM'lı hastalarda ciddi böbrek fonksiyon bozukluğunun en sık rastlanan nedeni silendir nefropatisidir (myelom böbreği). Hiperkalsemi, hiperürisemi, nefrotoksik ilaçlar, volüm azalması ve kontrast madde kullanımı myeloma özgü olmayan diğer böbrek hasarı yapan nedenlerdir. Günümüzde, kemoterapi ajanları, kök hücre nakli, plazmaferez ve diyaliz tekniklerindeki son gelişmelerin MM sağkalımını ve myeloma ilişkili böbrek hasarında prognozu düzelttiği görülmektedir. Ancak, myelomadaki yüksek heterojenite nedeniyle hastaların tedaviye yanıtı farklıdır. Bu yazıda, myelomalı hastalarda farklı böbrek tutulumu formları ile güncel tedavi yaklaşımları gözden geçirilmiştir
Anahtar Kelime: Konular:
Multiple Myeloma Kidney
Öz: Kidney injury is a common complication of symptomatic multiple myeloma (MM) and has an impact on the survival of patients. Cast nephropathy (myeloma kidney) is the most common cause of severe kidney dysfunction in MM. Hypercalcemia, hyperuricemia, volume depletion, usage of nephrotoxic agents and radiocontrast are the other non-myeloma specific reasons for kidney injury. Recent advances in chemotherapeutic agents, stem cell transplantation, plasma exchange and dialysis techniques seem to improve survival of MM and the prognosis of myeloma-associated kidney injury. However, responsiveness to treatment differs considerably among patients because of the high heterogeneity of myeloma. Herein, we review different forms of renal involvement and current therapeutic approaches in patients with myeloma
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757
- Türk Hematoloji Derneği: Ulusal Tanı ve Tedavi Kılavuzu 2013: Multipl Miyelom Tanı ve Tedavi Kılavuzu (2. basım). ISBN: 978- 605-4334-69-8. 2013;1-54
- Röllig C, Knop S, Bornhäuser M: Multiple myeloma. Lancet 2015;385(9983):2197-2208
- yaşında etiyolojisi bilinmeyen nefropatili bir erkek hastada da
- Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT: Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005;23:9219-9226
- Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A,Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J: Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-4984
- Heher EC, Rennke HG, Laubach JP, Richardson PG: Kidney disease and multiple myeloma. Clin J Am Soc Nephrol 2013;8:2007-2017
- Sengul S, Li M, Batuman V: Myeloma kidney: Toward its prevention--with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009;22:17-28
- Leung N, Nasr SH: Myeloma-related kidney disease. Adv Chronic Kidney Dis 2014;21:36-47
- Al-Hussain T, Hussein MH, Al Mana H, Akhtar M: Renal involvement in monoclonal gammopathy. Adv Anat Pathol 2015;22:121-134
- Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33
- Fasola FA, Eteng KI, Shokunbi WA, Akinyemi JO, Salako BL: Renal status of multiple myeloma patients in ibadan, Nigeria. Ann Ib Postgrad Med 2012;10:28-33
- Lu J, Lu J, Chen W, Huo Y, Huang X, Hou J; Chinese Medical Doctor Association Hematology Branch: Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: Results of a multicenter analysis. Blood Cancer J 2014;4:e239
- Bladé J, Lust JA, Kyle RA: Immunoglobulin D multiple myeloma: Presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994;12:2398-2404
- Sungur C: Plazma hücre diskrazileri ile ilişkili böbrek hastalıkları ve amiloidoz. Arık N, Dilek M (eds), Nefroloji (2.baskı). İstanbul: Karakter Color A.Ş, 2008;127-138
- Ganeval D, Cathomen M, Noel LH, Grünfeld JP: Kidney involvement in multiple myeloma and related disorders. Contrib Nephrol 1982;33:210-222
- Pirani CL, Silva F, D'Agati V, Chander P, Striker LM: Renal lesions in plasma cell dyscrasias: Ultrastructural observations. Am J Kidney Dis 1987;10:208-221
- Erdur FM, Soyoral YU, Emre H, Beğenik H, Canbaz ET, Erkoç R: Multiple myelomlu olguda hiperkalseminin hemodiyaliz ile tedavisi. Tıp Araştırmaları Dergisi 2013; 11(Ek 1/Onkoloji):23-25
- Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, Dimopoulos MA: Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG). Leukemia 2009;23:1152-1157
- Suzuki K: Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol 2013;43:116-124
- Jurczyszyn A, Legie? W, Helbig G, Hus M, Kyrcz-Krzemie? S, Skotnicki AB: New drugs in multiple myeloma - role of carfilzomib and pomalidomide. Contemp Oncol (Pozn) 2014;18:17-21
- Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S: Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753-1761
- Kourelis TV, Manola A, Moustakakis MN, Bilgrami SF: Role of plasma exchange in the treatment of myeloma nephropathy: Experience of one institution and systematic review. Conn Med 2013;77:147-151
- Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN; Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 2005;143:777-784
- Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008;73:1282-1288
- Burnette BL, Leung N, Rajkumar SV: Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011;364:2365-2366
- Haspel RL, Cserti-Gazdewich C, Dzik WH: Renal improvement in myeloma with plasma exchange. N Engl J Med 2011;365:1061- 1062
- Rodrigues L, Neves M, Sá H, Gomes H, Pratas J, Campos M: Severe acute kidney injury and multiple myeloma: Evaluation of kidney and patient prognostic factors. Eur J Intern Med 2014;25:652-656
- Tsakiris DJ, Stel VS, Finne P, Fraser E, Heaf J, de Meester J, Schmaldienst S, Dekker F, Verrina E, Jager KJ: Incidence and outcome of patients starting renal replacement therapy for end- stage renal disease due to multiple myeloma or light-chain deposit disease: An ERA-EDTA Registry study. Nephrol Dial Transplant 2010;25:1200-1206
- Abbott KC, Agodoa LY: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival. Clin Nephrol 2001;56:207-210
- Shebl FM, Warren JL, Eggers PW, Engels EA: Cancer risk among elderly persons with end-stage renal disease: A population-based case-control study. BMC Nephrol 2012;13:65
- Shetty A, Oreopoulos DG: Continuous ambulatory peritoneal dialysis in end-stage renal disease due to multiple myeloma. Perit Dial Int 1995;15:236-240
- Clark AD, Shetty A, Soutar R: Renal failure and multiple myeloma: Pathogenesis and treatment of renal failure and management of underlying myeloma. Blood Rev 1999;13:79-90
- Heyne N, Denecke B, Guthoff M, Oehrlein K, Kanz L, Häring HU, Weisel KC: Extracorporeal light chain elimination: High cut-off (HCO) hemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury. Ann Hematol 2012;91:729- 735
- Hutchison CA, Heyne N, Airia P, Schindler R, Zickler D, Cook M, Cockwell P, Grima D: Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. Nephrol Dial Transplant. 2012;27:3823- 3828
- Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG: Presentation and survival of patients with severe acute kidney injury and multiple myeloma: A 20-year experience from a single centre. Nephrol Dial Transplant 2010;25:419-426
- Shehata N, Walker I, Meyer R, Haynes AE, Imrie K; Cancer Care Ontario Hematology Disease Site Group: The use of erythropoiesis- stimulating agents in patients with non-myeloid hematological malignancies: A systematic review. Ann Hematol 2008;87:961-973
- Heher EC, Spitzer TR, Goes NB: Light chains: Heavy burden in kidney transplantation. Transplantation 2009;87:947-952
- Alchi B, Nishi S, Iguchi S, Shimotori M, Sakatsume M, Ueno M, Narita I, Saito K, Takahashi K, Gejyo F: Recurrent light and heavy chain deposition disease after renal transplantation. Nephrol Dial Transplant 2005;20:1487-1491
- Leung N, Lager DJ, Gertz MA, Wilson K, Kanakiriya S, Fervenza FC: Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004;43:147-153
- Kuypers DR, Lerut E, Claes K, Evenepoel P, Vanrenterghem Y: Recurrence of light chain deposit disease after renal allograft transplantation: Potential role of rituximab? Transpl Int 2007;20:381-385
- Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L: Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: A case report. Transplant Proc 2009;41:4407-4410
- Moiz A, Javed T, Garces J, Staffeld-Coit C, Paueksakon P: Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: A case report. Ochsner J 2014;14:445-449
- Wagner L, Lengyel L, Mikala G, Reményi P, Piros L, Csomor J, Fábry L, Tordai A, Langer RM, Masszi T: Successful treatment of renal failure caused by multiple myeloma with HLA-identical living kidney and bone marrow transplantation: A case report. Transplant Proc 2013;45:3705-3707
- Spitzer TR, Sykes M, Tolkoff-Rubin N, Kawai T, McAfee SL, Dey BR, Ballen K, Delmonico F, Saidman S, Sachs DH, Cosimi AB: Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011;91:672-676
- Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N: Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol 2012;35:365-371
- Safadi S, Dispenzieri A, Amer H, Gertz MA, Rajkumar SV, Hayman SR, Lacy MQ, Leung N: Multiple myeloma after kidney transplantation. Clin Transplant 2015;29:76-84
- Savenkoff B, Aubertin P, Ladriere M, Hulin C, Champigneulle J, Frimat L: A de novo monoclonal immunoglobulin deposition disease in a kidney transplant recipient: A case report. J Med Case Rep 2014;8:205
- Aoki T, Kasai M, Harada Y, Matsubara E, Morishita T, Suzuki T, Tsujita M, Goto N, Katayama A, Watarai Y, Uchida K, Ito M, Saji H, Tsuzuki T, Uchida T, Ogura M: Stable renal engraftment in a patient following successful tandem autologous/reduced-intensity conditioning allogeneic transplantation for treatment of multiple myeloma with del (17p) that developed as a post-transplantation lymphoproliferative disease following renal transplantation. Int J Hematol 2013;98:129-134
- Goel SK, Granger D, Bellovich K, Marin M, Qu H, El-Ghoroury M: Myeloma cast nephropathy: A rare cause of primary renal allograft dysfunction. Transplant Proc 2011;43:2784-2788
| APA | Ayar Y, ERSOY A, YILDIZ A (2015). Multipl Myeloma Böbreği. , 256 - 265. |
| Chicago | Ayar Yavuz,ERSOY ALPARSLAN,YILDIZ ABDULMECİT Multipl Myeloma Böbreği. (2015): 256 - 265. |
| MLA | Ayar Yavuz,ERSOY ALPARSLAN,YILDIZ ABDULMECİT Multipl Myeloma Böbreği. , 2015, ss.256 - 265. |
| AMA | Ayar Y,ERSOY A,YILDIZ A Multipl Myeloma Böbreği. . 2015; 256 - 265. |
| Vancouver | Ayar Y,ERSOY A,YILDIZ A Multipl Myeloma Böbreği. . 2015; 256 - 265. |
| IEEE | Ayar Y,ERSOY A,YILDIZ A "Multipl Myeloma Böbreği." , ss.256 - 265, 2015. |
| ISNAD | Ayar, Yavuz vd. "Multipl Myeloma Böbreği". (2015), 256-265. |
| APA | Ayar Y, ERSOY A, YILDIZ A (2015). Multipl Myeloma Böbreği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, 24(3), 256 - 265. |
| Chicago | Ayar Yavuz,ERSOY ALPARSLAN,YILDIZ ABDULMECİT Multipl Myeloma Böbreği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 24, no.3 (2015): 256 - 265. |
| MLA | Ayar Yavuz,ERSOY ALPARSLAN,YILDIZ ABDULMECİT Multipl Myeloma Böbreği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, vol.24, no.3, 2015, ss.256 - 265. |
| AMA | Ayar Y,ERSOY A,YILDIZ A Multipl Myeloma Böbreği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi. 2015; 24(3): 256 - 265. |
| Vancouver | Ayar Y,ERSOY A,YILDIZ A Multipl Myeloma Böbreği. Türk Nefroloji Diyaliz ve Transplantasyon Dergisi. 2015; 24(3): 256 - 265. |
| IEEE | Ayar Y,ERSOY A,YILDIZ A "Multipl Myeloma Böbreği." Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, 24, ss.256 - 265, 2015. |
| ISNAD | Ayar, Yavuz vd. "Multipl Myeloma Böbreği". Türk Nefroloji Diyaliz ve Transplantasyon Dergisi 24/3 (2015), 256-265. |
